Publications by authors named "E Simoes"
Article Synopsis
- Clesrovimab is a new monoclonal antibody designed to prevent respiratory syncytial virus (RSV) disease in infants, tested in a study with 183 healthy infants aged 2 weeks to 8 months.
- The study found that Clesrovimab was well tolerated, with the most common side effect being irritability, and it demonstrated a long half-life of 44.9 days, along with improved serum neutralizing antibodies over time.
- Infants who received Clesrovimab had lower rates of RSV-related illnesses compared to those given a placebo, indicating its potential effectiveness for further development in clinical trials.
Objectives: This feasibility study evaluated the effectiveness of Support-Engage-Empower-Diabetes (SEE-Diabetes), a patient-centered educational tool designed to promote shared decision-making of diabetes management in older adults. We aimed to assess SEE-Diabetes's ability to facilitate patient engagement and collaborative goal setting, as measured by the Observational Patient Involvement (OPTION) scale and Shared Decision-Making Questionnaire (SDM-Q-Doc). We hypothesized that these instruments would effectively differentiate between healthcare providers who actively leveraged SEE-Diabetes to guide patient-centric conversations and set goals compared to those who did not.
View Article and Find Full Text PDFBackground: The WHO estimates that close to 1.7 billion people worldwide have hearing loss; 34 million of whom are children, with 90% residing in low- and middle-income countries. While the effects of ear disease and hearing loss on language, academic, and behavioral development are established, there is remarkably little data on intellectual and other cognitive differences.
View Article and Find Full Text PDFBackground: Severely underweight (SUW) children contribute significantly to under-five mortality and morbidity. There are WHO guidelines for the management of severe acute malnutrition but no specific guidelines for SUW management.
Objective: The objectives were to achieve a recovery rate of 30% at 90 days of treatment for severe underweight (SUW) children aged 6-60 months, compare changes in weight-for-age Z (WAZ) scores, growth patterns, and case fatality rates between intervention and reference arms (RA), and reduce the prevalence of SUW in the intervention arm (IA).
Article Synopsis
- New options for RSV prevention, such as the monoclonal antibody nirsevimab and the RSVpreF maternal vaccine, are being implemented to protect infants during their first RSV season, but countries are adopting these strategies at different rates.!
- A study analyzing data from 47 children's hospitals revealed that infants born at the start of the RSV season are significantly more likely to be hospitalized for RSV compared to those born earlier, and both prevention strategies could greatly reduce hospitalizations.!
- The findings indicate that more targeted strategies may be necessary, as current recommendations for nirsevimab might not be cost-efficient for all infants, particularly those born outside the RSV season or later in it; maternal immunization timing may need adjustment for better effectiveness